🚨 STOCK TO WATCH 🚨
₹1,050–₹1,060 → ₹1,374 → ₹1,530 → ₹3,113 👀
A fast-growing integrated pharmaceutical player appearing on my Weekly R4 Breakout Scanner.
Innova Captab Ltd.
📌 Buy Zone: ₹1,050–₹1,060
📌 Breakout Zone: ₹1,060
🛑 Stop Loss: ₹710
🎯 Target 1: ₹1,374
🎯 Target 2: ₹1,530
🎯 Target 3: ₹3,113
Why Innova Captab?
💊 Integrated pharma platform: The company operates across CDMO and Branded Generics, covering research, development, manufacturing and market-facing pharma operations.
🌍 Strong CDMO franchise: CDMO revenue reached ₹1,133.35 Cr in FY26, growing 23.8% YoY, with 350+ customers across 60+ countries.
📈 Branded Generics acceleration: FY26 Branded Generics revenue reached ₹496.67 Cr, representing 51.4% YoY growth.
🏭 Capacity expansion: The company has manufacturing facilities across Baddi, Dehradun, Taloja and Kathua, with further investment in manufacturing and R&D capabilities.
🌐 Export opportunity: Exports contributed 31.3% of FY26 revenue, with presence across 60+ countries and growing access to regulated markets.
📊 Weekly Camarilla R4 Breakout Setup
Why It Caught My Attention
✅ Strong CDMO growth
✅ 51%+ Branded Generics growth
✅ 350+ global customers
✅ Expanding manufacturing capacity
✅ Growing international exposure
✅ Weekly R4 Momentum Breakout
⚠️ High Risk – High Reward Setup. Always follow strict stop-loss and disciplined position sizing.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
Risk Defined. Reward Visible.
© 20K Microcap Investing | R4 Momentum Desk
#InnovaCaptab #PharmaStocks #CDMO #Pharmaceuticals #PharmaIndia #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
₹1,050–₹1,060 → ₹1,374 → ₹1,530 → ₹3,113 👀
A fast-growing integrated pharmaceutical player appearing on my Weekly R4 Breakout Scanner.
Innova Captab Ltd.
📌 Buy Zone: ₹1,050–₹1,060
📌 Breakout Zone: ₹1,060
🛑 Stop Loss: ₹710
🎯 Target 1: ₹1,374
🎯 Target 2: ₹1,530
🎯 Target 3: ₹3,113
Why Innova Captab?
💊 Integrated pharma platform: The company operates across CDMO and Branded Generics, covering research, development, manufacturing and market-facing pharma operations.
🌍 Strong CDMO franchise: CDMO revenue reached ₹1,133.35 Cr in FY26, growing 23.8% YoY, with 350+ customers across 60+ countries.
📈 Branded Generics acceleration: FY26 Branded Generics revenue reached ₹496.67 Cr, representing 51.4% YoY growth.
🏭 Capacity expansion: The company has manufacturing facilities across Baddi, Dehradun, Taloja and Kathua, with further investment in manufacturing and R&D capabilities.
🌐 Export opportunity: Exports contributed 31.3% of FY26 revenue, with presence across 60+ countries and growing access to regulated markets.
📊 Weekly Camarilla R4 Breakout Setup
Why It Caught My Attention
✅ Strong CDMO growth
✅ 51%+ Branded Generics growth
✅ 350+ global customers
✅ Expanding manufacturing capacity
✅ Growing international exposure
✅ Weekly R4 Momentum Breakout
⚠️ High Risk – High Reward Setup. Always follow strict stop-loss and disciplined position sizing.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
Risk Defined. Reward Visible.
© 20K Microcap Investing | R4 Momentum Desk
#InnovaCaptab #PharmaStocks #CDMO #Pharmaceuticals #PharmaIndia #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.